RECOMBINANT ALBUMIN FUSION PROTEINS - Fusion Protein Technologies for Biopharmaceuticals: Applications and Challenges - page 171

cleared in vivo retains the ability to inhibit platelet aggregation
in vitro. Thromb. Haemost. 86, 902-908.
34. Huang YJ, Lundy PM, Lazaris A, Huang Y, Baldassarre H,
Wang B, et al. (2008) Substantially improved pharmaco-
kinetics of recombinant human butyrylcholinesterase by fusion
to human serum albumin. BMC Biotechnol . 8, 50.
35. Brimijoin S, Gao Y, Anker JJ, Gliddon LA, Lafleur D, Shah R,
et al. (2008) A cocaine hydrolase engineered from human
butyrylcholinesterase selectively blocks cocaine toxicity and
reinstatement of drug seeking in rats. Neuropsychopharmacol-
ogy 33, 2715-2725.
36. Gao Y, LaFleur D, Shah R, Zhao Q, Singh M, Brimijoin S.
(2008) An albumin-butyrylcholinesterase for cocaine toxicity
and addiction: catalytic and pharmacokinetic properties.
Chem. Biol. Interact. 175, 83-87.
37. Cooper ZD, Narasimhan D, Sunahara RK, Mierzejewski P,
Jutkiewicz EM, Larsen NA, et al. (2006) Rapid and robust
protection against cocaine-induced lethality in rats by the
bacterial cocaine esterase. Mol. Pharmacol. 70, 1885-1891.
38. Joung CH, Shin JY, Koo JK, Lim JJ, Wang JS, Lee SJ, et al.
(2009) Production and characterization of long-acting recom-
binant human albumin-EPO fusion protein expressed in CHO
cell. Protein Expr. Purif. 68, 137-145.
39. Zollner S, Weimer T, Schmidbauer S, Raquet E, Mueller-Cohrs
J, Schulte S. (2010) Pharmacokinetics of a recombinant albu-
min-fused, human coagulation factor VIIa (rVIIa-FP) exhibit-
ing prolonged serum half-life in different animal species.
Haemophilia 16 (Suppl. 4), 33 [Abstract 07P24].
40. Syed S, Schuyler PD, Kulczycky M, Sheffield WP. (1997)
Potent antithrombin activity and delayed clearance from the
circulation characterize recombinant hirudin genetically fused
to albumin. Blood 89, 3243-3252.
41. Hatton MW, Ross-Ouellet B. (1994) Radiolabeled r-hirudin as
a measure of thrombin activity at, or within, the rabbit aorta
wall in vitro and in vivo. Thromb. Haemost. 71, 499-506.
42. Hagedorn I, Schmidbauer S, Pleines I, Kleinschnitz C,
Kronthaler U, Stoll G, et al. (2010) Factor XIIa inhibitor
recombinant human albumin Infestin-4 abolishes occlusive
arterial thrombus formation without affecting bleeding. Circu-
lation 121, 1510-1517.
43. Duttaroy A, Kanakaraj P, Osborn BL, Schneider H, Pickeral
OK, Chen C, et al. (2005) Development of a long-acting insulin
analog using albumin fusion technology. Diabetes 54, 251-
258.
44. Cresto JC, Lavine RL, Buchly ML, Pnehos JC, Bhathena SJ,
Recant L. (1977) Half-life of injected 125 I-insulin in control and
ob/ob mice. Acta Physiol. Latino Ame. 27, 7-15.
45. Ikuta S, Chuang VTG, Ishima Y, Nakajou K, Furukawa M,
Watanabe H, et al. (2010) Albumin fusion of thioredoxin - the
production and evaluation of its biological activity for potential
therapeutic applications. J. Control. Rel. 147, 17-23.
46. Ancell CD, Phipps J, Young L. (2001) Thymosin alpha-1. Am.
J. Health-Syst. Pharm. 58, 879-885.
47. M € uller D, Schneider B, Pfizenmaier K, Wajant H. (2010)
Superior serum half life of albumin tagged TNF ligands.
Biochem. Biophys. Res. Commun. 396, 793-799.

48. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G,
Gon S c ales F.L. Jr., et al. (2002) Peginterferon alfa-2a plus
ribavirin for chronic hepatitis C virus infection. N. Engl. J.
Med. 347, 975-982.
49. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiff-
man M, Reindollar R, et al. (2001) Peginterferon alfa-2b plus
ribavirin compared with interferon alfa-2b plus ribavirin for
initial treatment of chronic hepatitis C: a randomised trial.
Lancet 358, 958-965.
50. Balan V, Nelson DR, Sulkowski MS, Everson GT, Lambiase
LR, Wiesner RH, et al. (2006) A Phase I/II study evaluating
escalating doses of recombinant human albumin-interferon-
alpha fusion protein in chronic hepatitis C patients who have
failed previous interferon-alpha-based therapy. Antivir. Ther.
11, 35-45.
51. Osborn BL, Olsen HS, Nardelli B, Murray JH, Zhou JX, Garcia
A, et al. (2002) Pharmacokinetic and pharmacodynamic stud-
ies of a human serum albumin-interferon- a fusion protein in
cynomolgus monkeys. J. Pharmacol.Exp. Ther. 303, 540-548.
52. Yeh P, Landais D, Lema ^ ıtre M, Maury I, Crenne JY, Becquart J,
et al. (1992) Design of yeast-secreted albumin derivatives for
human therapy: biological and antiviral properties of a serum
albumin-CD4 genetic conjugate. Proc. Natl. Acad. Sci. USA
89, 1904-1908.
53. Perry CM, Jarvis B. (2001) Peginterferon-alpha-2a (40 kDa): a
review of its use in the management of chronic hepatitis C.
Drugs 61, 2263-2288.
54. Glue P, Fang JW, Rouzier-Panis R, Raffanel C, Sabo R, Gupta
SK, et al. (2000) Pegylated interferon-alpha2b: pharmaco-
kinetics, pharmacodynamics, safety, and preliminary efficacy
data. Clin. Pharmacol. Ther. 68, 556-567.
55. Nelson D, Benhamou Y, Chuang WL, Lawitz E, Flisiak R,
et al. (2009) Efficacy and safety results of albinterferon alfa-2b
in combination with ribavirin in interferon-alfa treatment naive
patients with genotype 2 or 3 chronic hepatitis C. J. Hepatol.
50 (Suppl. 1), S378 [Abstract 1042].
56. Nelson DR, Rustgi V, Balan V, Sulkowski MS, Davis GL, Muir
AJ, et al. (2009) Safety and antiviral activity of albinterferon
alfa-2b in prior interferon nonresponders with chronic hepatitis
C. Clin. Gastroenterol. Hepatol. 7, 212-218.
57. European Medicines Agency. Withdrawn Applications: Joul-
feron. Available at http://www.ema.europa.eu/ema/index.jsp?
curl ¼ pages/medicines/human/medicines/002166/wapp/Initia-
l_authorisation/human_wapp_000096.jsp&murl ¼ menus/
medicines/medicines.jsp&mid ¼ WC0b01ac058001d128&-
source ¼ homeMedSearch&category ¼ human (last accessed

September 23, 2010).
58. Rosenstock J, Reusch J, Bush M, Yang F, Stewart M. (2009)
Albiglutide study group. Potential of albiglutide, a long-acting
GLP-1 receptor agonist, in type 2 diabetes. Diabetes Care 32,
1880-1886.
59. Eng J, Kleinman WA, Singh L, Singh G, Raufman JP. (1992)
Isolation and characterization of exendin-4, an exendin-3
analogue, from Heloderma suspectum venom. Further evi-
dence for an exendin receptor on dispersed acini from guinea
pig pancreas. J. Biol. Chem. 267, 7402-7405.